Shares in Acadia Pharmaceuticals (ACAD) plunged 12% in Monday’s extended trading, after the company announced disappointing top-line results from its 298 patient Phase 3 CLARITY study evaluating pimavanserin as an adjunctive treatment for major depressive disorder (MDD).The study did not achieve statistical significance on the primary endpoint which was the 17-item Hamilton Depression Rating Scale (HAMD-17) total score change from baseline to week 5. Pimavanserin 34 mg, given once-daily as an adjunctive treatment to standard my-depression-treatment.com was associated with a mean reduction of 9.0 in HAMD-17 total score compared to 8.1 for placebo as an adjunctive treatment (p=0.296).Positive results …read more
Source:: Yahoo Finance
